ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Akihiko Okamura; Satoru Matsuda; Hirofumi Kawakubo; Shinji Mine; Hiroya Takeuchi; Yuko Kitagawa; Masayuki Watanabe

doi:10.1245/s10434-020-08772-4

ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Akihiko Okamura, Satoru Matsuda, Hirofumi Kawakubo, Shinji Mine, Hiroya Takeuchi, Yuko Kitagawa, Masayuki Watanabe

研究成果: Comment/debate › 査読

本文言語	English
ページ（範囲）	795-796
ページ数	2
ジャーナル	Annals of Surgical Oncology
巻	27
DOI	https://doi.org/10.1245/s10434-020-08772-4
出版ステータス	Published - 2020 12月

ASJC Scopus subject areas

外科
腫瘍学

文献へのアクセス

10.1245/s10434-020-08772-4

他のファイルとリンク

引用スタイル

@article{51a2302e9e944fefada7721074337c7b,

title = "ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma",

author = "Akihiko Okamura and Satoru Matsuda and Hirofumi Kawakubo and Shinji Mine and Hiroya Takeuchi and Yuko Kitagawa and Masayuki Watanabe",

note = "Funding Information: None declared conflicts of interests for this study. Conflicts of interests outside this work are as follows; Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, Sanofi K.K. grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical. ",

year = "2020",

month = dec,

doi = "10.1245/s10434-020-08772-4",

language = "English",

volume = "27",

pages = "795--796",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer New York",

}

TY - JOUR

T1 - ASO Author Reflections

T2 - Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

AU - Okamura, Akihiko

AU - Matsuda, Satoru

AU - Kawakubo, Hirofumi

AU - Mine, Shinji

AU - Takeuchi, Hiroya

AU - Kitagawa, Yuko

AU - Watanabe, Masayuki

N1 - Funding Information: None declared conflicts of interests for this study. Conflicts of interests outside this work are as follows; Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, Sanofi K.K. grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85087300733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087300733&partnerID=8YFLogxK

U2 - 10.1245/s10434-020-08772-4

DO - 10.1245/s10434-020-08772-4

M3 - Comment/debate

C2 - 32591950

AN - SCOPUS:85087300733

SN - 1068-9265

VL - 27

SP - 795

EP - 796

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

ER -